PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. Sep 1996; 74(6): 961–963.
PMCID: PMC2074723
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. van Meerbeeck, C. Debruyne, N. van Zandwijk, P. E. Postmus, M. C. Pennucci, F. van Breukelen, D. Galdermans, H. Groen, P. Pinson, M. van Glabbeke, E. van Marck, and G. Giaccone
University of Antwerp, Belgium.
Abstract
The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (673K), or click on a page image below to browse page by page.
Articles from British Journal of Cancer are provided here courtesy of
Cancer Research UK